Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 15/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.87 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074118 | 1.00 | MCHR1 (0.87) | MCHR1KCNH2MEN1MAPK1KMT2A | |
| SCHEMBL4066961 | 0.93 | MCHR1 (1.00) | MCHR1KCNH2 | |
| SCHEMBL4066972 | 0.93 | MCHR1 (1.00) | MCHR1KCNH2 | |
| SCHEMBL4068858 | 0.93 | MCHR1 (1.00) | MCHR1KCNH2 | |
| SCHEMBL4073561 | 0.87 | MCHR1 (0.78) | MCHR1KCNH2 | |
| SCHEMBL4073566 | 0.87 | MCHR1 (0.78) | MCHR1KCNH2 | |
| SCHEMBL4067114 | 0.87 | MCHR1 (0.89) | MCHR1KCNH2 | |
| SCHEMBL4067107 | 0.87 | MCHR1 (0.89) | MCHR1KCNH2 | |
| SCHEMBL4069016 | 0.86 | MCHR1 (0.79) | MCHR1KCNH2 | |
| SCHEMBL4069018 | 0.86 | MCHR1 (0.79) | MCHR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| EP-2072519-A1 | DIARYL KETIMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | NR0B2, NR2C2, NR3C2 | MCHR1 730/4885KCNH2 296/4885MEN1 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.